MapLight Therapeutics, Inc. (MPLT) Stock
Healthcare · Biotechnology · Member of Other US Stocks
MapLight Therapeutics, Inc. (MPLT) closed at USD 7.81 on 2026-10-14, a change of -53.4 % over the past year, with a market capitalization of USD 445.72M.
MapLight Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 7.81 |
| 2026-10-13 | 7.88 |
| 2026-10-12 | 8.60 |
| 2026-10-09 | 8.83 |
| 2026-10-08 | 9.15 |
| 2026-10-07 | 9.36 |
| 2026-10-06 | 9.69 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
MapLight Therapeutics, Inc. key figures
- Previous close
- USD 7.81 (2026-10-14)
- 1-year change
- -53.4 %
- Market cap
- USD 445.72M
- Enterprise value
- USD 69.21M
- P/E ratio (trailing)
- -1.26
- P/E ratio (forward)
- -2.35
- EPS (trailing)
- -6.37
- EPS (forward)
- -3.42
- PEG ratio
- n/a
- Price to book
- 1.05
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 5.74
- Employees
- 133
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for MapLight Therapeutics, Inc. and compare it with other stocks.
Analyze MPLTAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell MapLight Therapeutics, Inc. shares.